A predictive endocrine resistance index accurately stratifies luminal breast cancer treatment responders and nonresponders.

doi:10.1172/JCI177813

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A predictive endocrine resistance index accurately stratifies luminal breast cancer treatment responders and nonresponders.

The Journal of clinical investigation - 1 Oct 2025

Zhang Guokun, Jurinovic Vindi, Bartels Stephan, Christgen Matthias, Christgen Henriette, Kandt Leonie Donata, Mishieva Lidiya, Ni Hua, Raap Mieke, Klein Janin, Katzke Anna-Lena, Hofmann Winfried, Steinemann Doris, Kates Ronald E, Gluz Oleg, Graeser Monika, Kümmel Sherko, Nitz Ulrike, Plass Christoph, Lehmann Ulrich, Zu Eulenburg Christine, Mansmann Ulrich, Gerhäuser Clarissa, Harbeck Nadia, Kreipe Hans H

Abstract excerpt

BACKGROUNDEndocrine therapy (ET) with tamoxifen (TAM) or aromatase inhibitors (AI) is highly effective against hormone receptor-positive (HR-positive) early breast cancer (BC), but resistance remains a major challenge. The primary objectives of our study were to understand the underlying mechanisms of primary resistance and to identify potential biomarkers.METHODSWe selected more than 800 patients in 3 subcohorts...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents, Hormonal

Share to Aromatase Inhibitors

Share to Breast Neoplasms

Share to DNA Methylation

Share to Drug Resistance, Neoplasm

Share to Tamoxifen

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 40705465
DOI: 10.1172/JCI177813
PMCID: PMC12483570

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A predictive endocrine resistance index accurately stratifies luminal breast cancer treatment responders and nonresponders.PMID 40705465Read ↗

Development and validation of multivariate predictors of primary endocrine resistance to tamoxifen and aromatase inhibitors in luminal breast cancer reveal drug-specific differencesSemantic proximity Read ↗

Decoding breast cancer treatment resistance through genetic, epigenetic, and immune-regulatory mechanisms: from molecular insights to translational perspectivesSemantic proximity Read ↗

TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer.Semantic proximity Read ↗

Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancerSemantic proximity Read ↗

Candidate methylation sites associated with endocrine therapy resistance in the TCGA ER+/HER2- breast cancer cohortSemantic proximity Read ↗

Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor–Positive Breast CancerSemantic proximity Read ↗

p53 Expression in Luminal Breast Cancer Correlates With TP53 Mutation and Primary Endocrine Resistance.Semantic proximity Read ↗

Decoding gene regulatory circuitry underlying TNBC chemoresistance reveals biomarkers for therapy response and therapeutic targetsSemantic proximity Read ↗

The Underlying Mechanisms and Emerging Strategies to Overcome Resistance in Breast CancerSemantic proximity Read ↗

Integrative analysis of pre-treatment RNA expression signatures and recurrent genomic alterations: Link to menopausal status, short-term endocrine therapy response and disease-free survival in luminal breast cancerSemantic proximity Read ↗

Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies.Semantic proximity Read ↗

Molecular basis for therapy resistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.